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Abstract
Subependymomas (SE) are slow-growing brain tumors that tend to occur within the ven-
tricles of middle-aged and elderly adults. The World Health Organization classiﬁes these
tumors within the ependymoma group. Previous limited analysis of this tumor type had not
revealed signiﬁcant underlying cytogenetic abnormalities.
We have used microarray comparative genomic hybridization to study a series of SE
(n = 12).A whole-genome array at 0.97-Mb resolution showed copy number abnormalities
in ﬁve of 12 cases (42%).Two cases (17%) showed regions of loss on chromosome 6. More
detailedanalysisofallcasesusingachromosome6tile-patharrayconﬁrmedthepresenceof
overlapping regions of loss in only these two cases. One of these cases also showed trisomy
chromosome 7. Monosomy of chromosome 8 was seen in a further two cases (17%), and
a partial loss on chromosome 14 was observed in one additional case.
This is the ﬁrst array-based, genome-wide study of SE. The observation that ﬁve of 12
cases examined (42%) at 0.97-Mb resolution showed chromosomal copy number abnor-
malities is a novel ﬁnding in this tumor type.
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INTRODUCTION
Subependymomas (SE) were ﬁrst described by Scheinker in 1945
(31).They are slow growing, benign neoplasms of uncertain histo-
genesis typically located within the ventricles (20). Most cases
of SE occur in middle or old age, and they are more frequent in
men than women (32). Prognosis is generally good, and surgical
removal alone is often curative (19, 24, 27, 28).
The true incidence of these tumors is unclear. In a series of 298
ependymal tumors examined by Schiffer et al, they accounted for
8.3% of cases (33). SE occur most frequently within the fourth
ventricle (50%–60%), followed by the lateral ventricles (30%–
40%) (20). Less common sites include the third ventricle, the
septum pellucidum and the spinal cord (16). In the vast majority of
cases, they develop sporadically, though very occasional familial
cases have been described (5, 6, 13, 30). One report describes
infratentorial SE occurring in two identical twins (6).
The proposed precursor cell of the SE is still controversial and
suggestions have included subependymal glia (1, 26), astrocytes of
the subependymal plate, ependymal cells (21, 29) and a mixture of
astrocytes and ependymal cells (4, 10). Recent work has proposed
radial glia as the cancer stem cell underlying ependymoma devel-
opment (10); however, similar studies of SE have not yet been
undertaken.
The histological appearance of SE is distinctive, comprised of
clusters of glial tumor cells embedded in an abundant ﬁbrillary
matrix (20). However, areas with subependymomal morphology
can be found in otherwise classical ependymomas (20).
Three previous cytogenetic studies using karyotypic analysis
of metaphase spreads looked at a total of six cases of SE. This
revealed no cytogenetic abnormalities in ﬁve cases, but in one
case with a normal karyotype, non-clonal structural abnormalities
were identiﬁed on the short arm of chromosome 17 (7, 8, 35). A
further study using ﬂow cytometry to assess DNA content in 15
cases found aneuploidy in one case of SE, and a higher than
normal proportion of cells in G2/M phase in two cases (21). Spe-
ciﬁc genetic analysis of two SE for allelic deletions on chromo-
somes 10q and 22q and for point mutations of the NF2 and PTEN
tumor suppressor genes did not reveal any changes at these loci
(9).
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comparative genomic hybridization techniques, in order to assess
the contribution of copy number change to the oncogenesis of SE.
We report two cases with copy number abnormalities on chromo-
some 6 and two cases with monosomy of chromosome 8, as well as
individual incidences of trisomy of chromosome 7 and one partial
lossonchromosome14.Toourknowledge,thisistheﬁrstgenome-
wide array-based study of SE.
MATERIALS AND METHODS
Patients, tumor tissue and DNA isolation
Primary tumor samples from 12 patients with a SE were included
in the analysis.The tumors were resected at the Karolinska Hospi-
tal, Stockholm, and the Sahlgrenska University Hospital, Gothen-
burg, Sweden between 1988 and 1997. Full ethical approval has
been given for this study. At resection, the median age of the
patients was 54 years (range 25–76 years). Patients’ gender, age at
resection and tumor location are described in Table 1. Histopatho-
logical classiﬁcation was undertaken according to World Health
Organization recommendations. All tumor pieces were selected
for DNA extraction after histological examination to ensure a
minimum of 80% tumor cells within the samples. DNA was
extracted from tumor pieces and blood lymphocytes as described
previously (21). Tumor samples were stored at -135°C and blood
samples at -20°C before DNA extraction. Extracted DNA was
stored at -80°C.
Microarray comparative genomic hybridization
A 0.97-Mb resolution whole genome microarray was constructed
with 3038 clones obtained from the Wellcome Trust Sanger Insti-
tute as described previously (9, 21). The chromosome 6 tile-path
arraycontains1780clones[778P1-derivedartiﬁcialchromosomes
and 1002 bacterial artiﬁcial chromosomes (BACs)] that cover
98.3% of the published chromosome 6 sequence. Construction
of this tile-path array has been described previously (14).
All labeling and hybridizations were performed as described
previously (15, 18). Brieﬂy, 400–800 ng of test and reference DNA
were labeled using a Bioprime Labeling Kit (Invitrogen, Carlsbad,
CA) with a modiﬁed dNTP reaction mixture. Test DNA was
hybridized with sex-mismatched reference DNA from samples
of pooled blood from 20 normal men or 20 normal women. The
labeled and puriﬁed DNA was co-precipitated with 45 mg Cot1
DNA (Roche Diagnostic, Mannheim, Germany). The precipitated
DNA was dissolved in hybridization buffer, incubated at 37°C for
2 h, and hybridized to the array that had been pre-hybridized with
480 mg herring sperm DNA (Sigma-Aldrich, St. Louis, MO) and
80 mg Cot1 DNA. Arrays were allowed to hybridize for up to 24 h
at 37°C and then washed and analyzed as previously described (15,
18). Scanning and analysis of the arrays, criteria for exclusion
of spots and scoring of copy number have also been described
previously (21).
RESULTS
Clinicopathological data for the samples as well as any changes
seenonthewhole-genomearrayaresummarizedinTable 1.SEare
more common in men than women, and this is reﬂected by this
series (9 men : 3 women). The median age at operation was 54
years. The majority of the tumors (9/12, 75%) were intraventricu-
lar, though individual cases located in the brainstem and spinal
cord were also included.
Most of the cases examined (7/12, 58%) showed normal copy
numberacrossthegenomeat0.97-Mbresolution.Fiveof12(42%)
cases showed abnormal copy number as shown in Table 1. SE3 and
SE12 showed loss of an entire chromosome 8, SE6 showed a
complex pattern of losses on chromosome 6 described in more
detail below, SE11 showed a gain of chromosome 7 and a partial
loss on chromosome 6 (-6q13-q15; maximally between RP3-
424L16 to RP1-23D17) and SE2 showed a partial loss of 14q21.1-
q31 shown in more detail below.
Two copy number alterations were seen in more than one case
each. Firstly, both SE3 and SE12 showed loss of one copy of chro-
mosome 8. Whole genome plots of SE3 and SE12 are shown in
Figure 1.
In addition, two cases (SE6 and SE11) showed small lengths
of overlapping copy number loss within chromosome 6 on the
whole genome array. As a result of identiﬁcation of these appar-
ently relatively small deletions, all cases were subjected to further
analysis at higher resolution on a chromosome 6 tiling-path array.
Table 1. Results of whole genome microarray
comparative genomic hybridization (aCGH).
Case ID Sex Age Location aCGH result
Gains Losses
SE1 M 69 Fourth ventricle
SE2 M 76 Fourth ventricle -14q21.1-q31.3
SE3 F 39 Right lateral ventricle -8
SE4 F 48 Right lateral ventricle
SE5 M 52 Fourth ventricle
SE6 F 49 Intramedullary Complex -6p/6q
SE7 M 52 Brainstem
SE8 M 56 Brainstem
SE9 M 25 Intraventricular
SE10 M 68 Fourth ventricle
SE11 M 56 Fourth ventricle +7 -6q13-q15
SE12 M 58 Intraventricular -8
Genome-Wide Array CGH of Subependymomas Kurian et al
470 Brain Pathology 18 (2008) 469–473
© 2008 The Authors; Journal Compilation © 2008 International Society of NeuropathologyThe minimal overlapping area of loss in SE6 and SE11 is a
10.01-Mb region between BACs RP11-398K22 and RP1-
202D23. The tiling-array plots from SE6 and SE11, along with
a schematic representation of the region of overlap are shown in
Figure 2. The remaining 10 cases were also examined with the
chromosome 6 tiling-path array and no further changes in this
region were identiﬁed.
SE2 showed a loss of 14q21.1-q31 (maximally between RP11-
33209 to RP11-203D9) which is shown in Figure 3.
Chromosomal copy number change was present in 2/3 of the
female cases compared with 3/9 male cases, but this was not a
signiﬁcant difference (P = 0.52, two-tailed Fisher’s exact test).
There was no signiﬁcant difference between the median age of the
patients with copy number change (56 years, n = 5) and those
without copy number change (52 years, n = 7). There was also no
relationship between tumor site and copy number alteration.
DISCUSSION
This study shows that most of the SE [7 of 12 cases (58%)] show
normal chromosomal copy number proﬁles at this resolution, in
keeping with previous work using traditional cytogenetic analysis
(7, 10, 36). However, this study shows for the ﬁrst time that a
signiﬁcant subset of SE [5 of 12 (42%)] show abnormal copy
number proﬁles.
Figure 1. Whole genome microarray comparative genomic hybridization of subependymoma (SE)3 and SE12 showing monosomy 8.
Figure 2. Chromosomal 6 tiling path array on subependymoma (SE)6 and SE11 showing the area of overlapping loss corresponding to the region of
loss seen on the 0.97 Mb resolution plot.
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mosomes 6 and 14, trisomy 7 and monosomy 8. In particular, two
cases showed overlapping regions of loss on chromosome 6q.Tile-
path array analysis conﬁrmed that the area in common is present
within two cases only (SE6 and SE11) and is a 10.01-Mb region
between BACs RP11-398K22 and RP1-202D23. This region con-
tains 40 gene entries in the Ensembl database which are given in
Table S1. Of the forty entries, HMGN3 and TTK tyrosine kinase
are candidates which could have tumor suppressor functions.
HMGN3 is a nucleosome-binding protein that has roles in chroma-
tinunfoldingandtranscriptionalcontrol(22,34).TTK,alsoknown
as MPS1, belongs to a family of enzymes which can phosphorylate
both serine/threonine and tyrosine residues and is involved in the
spindle assembly checkpoint (37, 38).
The other ﬁndings such as monosomy 8 and trisomy of chromo-
some 7 have been described in many different tumors. Monosomy
8 has been described in conjunction with other genetic abnormali-
ties in prostatic adenocarcinoma (12, 25).Trisomy 7 has also been
reported in peritumoural, non-neoplastic tissues and cell cultures
fromnormalbrain(2,11,39),andithasbeensuggestedthatgainof
chromosome 7 in neoplastic and non-neoplastic tissues may be
an aging phenomenon (3, 17).
The cytogenetic ﬁndings in our study are quite distinct from
those commonly found in certain other tumors within the ependy-
moma group: for example loss of 22q within spinal ependymomas
(35) and gain of chromosomes 9 and 18 within myxopapillary
ependymomas (23). None of the tumors examined in this study
showed a mixed SE/ependymoma morphology.
Weshowfortheﬁrsttimethatrelativelylargegeneticabnormali-
ties occur within SE and indicate that further studies at higher
resolution are appropriate to elucidate the cellular processes
involved in the development of these tumors.
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